DK0957917T3 - Vitronectinreceptorantagonister - Google Patents

Vitronectinreceptorantagonister

Info

Publication number
DK0957917T3
DK0957917T3 DK97909979T DK97909979T DK0957917T3 DK 0957917 T3 DK0957917 T3 DK 0957917T3 DK 97909979 T DK97909979 T DK 97909979T DK 97909979 T DK97909979 T DK 97909979T DK 0957917 T3 DK0957917 T3 DK 0957917T3
Authority
DK
Denmark
Prior art keywords
receptor antagonists
vitronectin receptor
vitronectin
antagonists
receptor
Prior art date
Application number
DK97909979T
Other languages
Danish (da)
English (en)
Inventor
James Francis Callahan
Russell Donovan Cousins
Richard Mccullock Keenan
Chet Kwon
William Henry Miller
Irene Nijole Uzinkas
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Application granted granted Critical
Publication of DK0957917T3 publication Critical patent/DK0957917T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/243Platinum; Compounds thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D223/00Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D223/00Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16Benzazepines; Hydrogenated benzazepines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/582Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DK97909979T 1996-10-02 1997-10-01 Vitronectinreceptorantagonister DK0957917T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2732096P 1996-10-02 1996-10-02
US4377697P 1997-04-11 1997-04-11

Publications (1)

Publication Number Publication Date
DK0957917T3 true DK0957917T3 (da) 2006-04-18

Family

ID=26702318

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97909979T DK0957917T3 (da) 1996-10-02 1997-10-01 Vitronectinreceptorantagonister

Country Status (36)

Country Link
EP (1) EP0957917B1 (cs)
JP (2) JP4491072B2 (cs)
KR (1) KR100589578B1 (cs)
CN (1) CN1114403C (cs)
AP (1) AP1463A (cs)
AR (1) AR008878A1 (cs)
AT (1) ATE312089T1 (cs)
AU (1) AU733417B2 (cs)
BG (1) BG64581B1 (cs)
BR (1) BR9712248B1 (cs)
CA (1) CA2267224C (cs)
CO (1) CO4900046A1 (cs)
CY (1) CY2576B1 (cs)
CZ (1) CZ299076B6 (cs)
DE (1) DE69734833T2 (cs)
DK (1) DK0957917T3 (cs)
DZ (1) DZ2320A1 (cs)
EA (1) EA002419B1 (cs)
ES (1) ES2252775T3 (cs)
HU (1) HU229221B1 (cs)
ID (1) ID19623A (cs)
IL (1) IL129243A (cs)
MA (1) MA24361A1 (cs)
MY (1) MY137606A (cs)
NO (1) NO320194B1 (cs)
NZ (1) NZ334953A (cs)
PE (1) PE10499A1 (cs)
PL (1) PL190859B1 (cs)
RO (1) RO119881B1 (cs)
SA (1) SA98180936B1 (cs)
SK (1) SK285029B6 (cs)
TR (1) TR199900737T2 (cs)
TW (1) TW487702B (cs)
UA (1) UA60311C2 (cs)
UY (2) UY24735A1 (cs)
WO (1) WO1998014192A1 (cs)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA60311C2 (uk) * 1996-10-02 2003-10-15 Смітклайн Бічам Корпорейшн Антагоністи рецептора вітронектину, спосіб одержання цих сполук та фармацевтична композиція
TW527355B (en) 1997-07-02 2003-04-11 Bristol Myers Squibb Co Inhibitors of farnesyl protein transferase
EP1017387A4 (en) * 1997-09-24 2004-08-18 Smithkline Beecham Corp VITRONEECT RECEPTOR ANTAGONIST
KR20010024249A (ko) * 1997-09-24 2001-03-26 스튜어트 알. 수터 비트로넥틴 수용체 길항제
US6372719B1 (en) * 1998-03-04 2002-04-16 Jay Cunningham ανβ3 integrin antagonists in combination with chemotherapeutic agents
DE19842415A1 (de) * 1998-09-16 2000-03-23 Merck Patent Gmbh Pharmazeutische Zubereitung
WO2000038786A2 (en) * 1998-12-23 2000-07-06 G.D. Searle & Co. Use of cyclooxygenase 2 inhibitor and an integrin antagonist as a combination therapy in the treatment of neoplasia
JP2002536370A (ja) * 1999-02-03 2002-10-29 メルク エンド カムパニー インコーポレーテッド α−Vインテグリン受容体拮抗薬としてのベンゾアゼピン誘導体
EP2062583B1 (en) * 1999-04-30 2012-12-26 The Regents of the University of Michigan Therapeutic applications of pro-apoptotic benzodiazepines
EP1208101A4 (en) * 1999-08-06 2003-03-19 Smithkline Beecham Corp VITRONECTIN RECEPTOR ANTAGONISTS USEFUL FOR THE TREATMENT OF VASCULAR ACCIDENTS
US6514964B1 (en) 1999-09-27 2003-02-04 Amgen Inc. Fused cycloheptane and fused azacycloheptane compounds and their methods of use
DE10027514A1 (de) * 2000-06-06 2002-01-03 Basf Ag Liganden von Integrinrezeptoren
DE10028575A1 (de) 2000-06-14 2002-03-14 Basf Ag Integrinliganden
FR2806082B1 (fr) * 2000-03-07 2002-05-17 Adir Nouveaux composes bicycliques antagonistes des recepteurs de la vitronectine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AU2002243692B2 (en) 2001-01-29 2006-06-08 3-Dimensional Pharmaceuticals, Inc. Substituted indoles and their use as integrin antagonists
ATE417612T1 (de) * 2001-04-10 2009-01-15 Smithkline Beecham Corp Verfahren zur unterdrückung von adhäsionsbildung
SE0101386D0 (sv) 2001-04-20 2001-04-20 Astrazeneca Ab New compounds
US7109191B2 (en) 2001-05-03 2006-09-19 Merck & Co., Inc. Benzazepinone alpha vintegrin receptor antagonists
EP2428226A1 (en) 2001-10-22 2012-03-14 The Scripps Research Institute Antibody targeting compounds
GB0215867D0 (en) * 2002-07-09 2002-08-14 Glaxosmithkline Spa Novel method and compounds
WO2004089890A2 (en) * 2003-04-04 2004-10-21 Smithkline Beecham Corporation Process and intermediates for preparing benzazepines
AU2012216372B2 (en) * 2004-04-02 2015-01-22 The Regents Of The University Of California Methods and compositions for treating and preventing disease associated with alphaVbeta5 integrin
CN1964740A (zh) * 2004-04-02 2007-05-16 加利福尼亚大学董事会 治疗和预防与αVβ5整联蛋白有关的疾病的方法和组合物
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
EP1841406A4 (en) * 2004-12-21 2008-06-25 Smithkline Beecham Corp METHOD AND FORMULATIONS
BRPI0619057A2 (pt) * 2005-11-29 2011-09-20 Smithkline Beecham Corp formulação farmacêutica de uso tópico, uso de um ou mais compostos, e, compostos
EP2730282A1 (en) 2007-11-08 2014-05-14 The General Hospital Corporation Methods and compositions for the treatment of proteinuric diseases
CA2705916C (en) * 2007-11-16 2016-01-05 Ube Industries, Ltd. Benzazepinone compound
EP2257538B1 (en) * 2008-03-06 2016-04-27 GlaxoSmithKline LLC Process for the preparation of benzodiazepine derivatives
EP2395992A2 (en) 2009-02-10 2011-12-21 The Scripps Research Institute Chemically programmed vaccination
EP2415474B1 (en) * 2009-03-30 2013-08-28 Ube Industries, Ltd. Pharmaceutical composition for treatment or prevention of ophthalmic diseases
JP5572996B2 (ja) * 2009-05-15 2014-08-20 宇部興産株式会社 ベンズアゼピノン化合物を有効成分として含有する医薬
IN2012DN00303A (cs) 2009-07-24 2015-05-08 Univ California
CN102753179A (zh) 2009-11-17 2012-10-24 密执安大学评议会 具有治疗性能的1,4-苯并二氮杂*-2,5-二酮和相关化合物
EP2325194A1 (en) * 2009-11-24 2011-05-25 Glycotope GmbH Process for the purification of glycoproteins
MX2016015467A (es) 2014-05-30 2017-03-23 Pfizer Derivados de carbonitrilo como moduladores selectivos del receptor de androgenos.
JP7693709B2 (ja) * 2020-04-26 2025-06-17 ジャンスー・エンファ・ファーマシューティカル・カンパニー・リミテッド 1,5-ジヒドロ-2,4-ベンゾジアゼピン-3-オン誘導体及びその使用
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0674623B1 (en) * 1992-12-21 2003-04-09 Smithkline Beecham Corporation Bicyclic fibrinogen antagonists
ZA955391B (en) * 1994-06-29 1996-02-09 Smithkline Beecham Corp Vitronectin receptor antagonists
MX9700041A (es) * 1994-06-29 1997-04-30 Smithkline Beecham Corp Antagonistas de receptor de vitronectina.
EP0777657A1 (en) * 1994-08-22 1997-06-11 Smithkline Beecham Corporation Bicyclic compounds
WO1996026190A1 (en) * 1995-02-22 1996-08-29 Smithkline Beecham Corporation Integrin receptor antagonists
UA60311C2 (uk) * 1996-10-02 2003-10-15 Смітклайн Бічам Корпорейшн Антагоністи рецептора вітронектину, спосіб одержання цих сполук та фармацевтична композиція

Also Published As

Publication number Publication date
BR9712248B1 (pt) 2010-06-29
ATE312089T1 (de) 2005-12-15
EA002419B1 (ru) 2002-04-25
KR100589578B1 (ko) 2006-06-15
NO991590L (no) 1999-05-31
CN1114403C (zh) 2003-07-16
AR008878A1 (es) 2000-02-23
EP0957917B1 (en) 2005-12-07
CZ113299A3 (cs) 2000-03-15
DE69734833D1 (de) 2006-01-12
SK42599A3 (en) 1999-12-10
AU733417B2 (en) 2001-05-17
AU4746297A (en) 1998-04-24
MY137606A (en) 2009-02-27
RO119881B1 (ro) 2005-05-30
CA2267224C (en) 2007-03-13
CA2267224A1 (en) 1998-04-09
ID19623A (id) 1998-07-23
BG103299A (en) 2000-01-31
HUP9903769A2 (hu) 2000-03-28
HU229221B1 (en) 2013-09-30
BG64581B1 (bg) 2005-08-31
PE10499A1 (es) 1999-03-27
EP0957917A1 (en) 1999-11-24
AP9901493A0 (en) 1999-03-31
SK285029B6 (sk) 2006-04-06
AP1463A (en) 2005-09-10
CY2576B1 (en) 2008-07-02
NZ334953A (en) 2000-01-28
WO1998014192A1 (en) 1998-04-09
TR199900737T2 (xx) 1999-07-21
IL129243A0 (en) 2000-02-17
MA24361A1 (fr) 1998-07-01
UY24735A1 (es) 1998-03-30
ES2252775T3 (es) 2006-05-16
DE69734833T2 (de) 2006-07-13
UA60311C2 (uk) 2003-10-15
EA199900356A1 (ru) 2000-02-28
KR20000048816A (ko) 2000-07-25
EP0957917A4 (en) 2002-05-15
CZ299076B6 (cs) 2008-04-16
PL190859B1 (pl) 2006-02-28
CN1238689A (zh) 1999-12-15
JP2010006838A (ja) 2010-01-14
PL332674A1 (en) 1999-09-27
NO991590D0 (no) 1999-03-31
DZ2320A1 (fr) 2002-12-28
UY24935A1 (es) 2001-07-31
CO4900046A1 (es) 2000-03-27
HK1023730A1 (en) 2000-09-22
HUP9903769A3 (en) 2000-07-28
IL129243A (en) 2004-07-25
SA98180936B1 (ar) 2006-05-30
JP2001501936A (ja) 2001-02-13
JP4491072B2 (ja) 2010-06-30
NO320194B1 (no) 2005-11-14
TW487702B (en) 2002-05-21
BR9712248A (pt) 1999-08-24

Similar Documents

Publication Publication Date Title
DK0957917T3 (da) Vitronectinreceptorantagonister
NO965608D0 (no) Vitronectin-reseptor-antagonister
BR9612381A (pt) Antagonistas receptores vitronectina
NO983003D0 (no) Vitronectin-reseptor-antagonister
NO983002D0 (no) Vitronectin-reseptor-antagonister
NO993350D0 (no) Vitronectin-reseptor-antagonister
DE69812096D1 (de) Neuropeptid y rezeptorantagonisten
NO972016D0 (no) Indolyl-Y-reseptorantagonister
NO986110D0 (no) IL-8 reseptor-antagonister
NO986109D0 (no) IL-8 reseptor-antagonister
ATE315035T1 (de) Ccr-3-rezeptor-antagonisten
NO990668D0 (no) IL-8 reseptor antagonister
EP0885205A4 (en) Fibrinogen Receptor Antagonists
ID24726A (id) Antagonis-antagonis reseptor trombin
NO20001514D0 (no) Vitronectin-reseptor-antagonist
NO20001407D0 (no) Vitronectin-reseptor-antagonister
NO20004503L (no) Vitronectin-reseptor-antagonister
NO20001515D0 (no) Vitronektin reseptor-antagonist
DK0906294T3 (da) Benzoxazinon-dopamin D4-receptor-antagonister
DZ2322A1 (fr) Antagonistes de récepteurs de vitronectine.
DE69920518D1 (de) Vitronectin rezeptor antagonist
NO20010620D0 (no) Vitronektinreseptor-antagonister
EP0957908A4 (en) FIBRINOGEN RECEPTOR ANTAGONISTS
SI0957917T1 (sl) Antagonisti receptorja vitronektina
DE69830671D1 (de) Integrin-rezeptor-antagonisten